Last reviewed · How we verify
Cosentyx (secukinumab)
Secukinumab selectively binds IL-17A cytokine and inhibits its interaction with IL-17 receptor.
Secukinumab is a human IgG1 monoclonal antibody IL-17A antagonist indicated for moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, enthesitis-related arthritis, and hidradenitis suppurativa across adult and pediatric populations. The drug demonstrates bioavailability of 55-77% with peak serum concentrations achieved approximately 6 days post-dose and steady-state achieved by Week 24 on every 4-week dosing. Serious hypersensitivity reactions including anaphylaxis and angioedema are contraindicated, and CYP450 substrate interactions require monitoring upon initiation or discontinuation. COSENTYX represents a targeted approach to IL-17A-mediated inflammatory diseases with established efficacy across multiple indications.
At a glance
| Generic name | secukinumab |
|---|---|
| Sponsor | Novartis |
| Drug class | IL-17A antagonist |
| Target | Interleukin-17A (IL-17A) |
| Modality | Monoclonal antibody |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 2015 |
| Annual revenue | 3900 |
Mechanism of action
Secukinumab is a human IgG1 monoclonal antibody that selectively binds to the interleukin-17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. By blocking IL-17A, secukinumab inhibits the release of proinflammatory cytokines and chemokines, thereby reducing the inflammatory cascade associated with various immune-mediated diseases.
Approved indications
- Ankylosing spondylitis
- Non-radiographic axial spondyloarthritis
- Plaque psoriasis
- Psoriatic arthritis
- Pustular psoriasis
Common side effects
- Nasopharyngitis
- Upper respiratory tract infection
- COVID-19
- Oral candidiasis
- Hyperuricaemia
- Hyperlipidaemia
- Urinary tract infection
- Arthralgia
- Headache
- Back pain
- Low density lipoprotein increased
- Intervertebral disc protrusion
Drug interactions
- CYP450 substrates
Key clinical trials
- BE RADIANT (PHASE3)
- Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa (PHASE3)
- Efficacy and Safety Study of Secukinumab in Chinese Participants With Non-radiographic Axial Spondyloarthritis (PHASE3)
- AgAIN (PHASE3)
- UnchAIN (PHASE3)
- Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy (PHASE3)
- An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA) (PHASE3)
- Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cosentyx CI brief — competitive landscape report
- Cosentyx updates RSS · CI watch RSS
- Novartis portfolio CI